Agenus Inc. (AGEN) Stock: A Good Pick In The Biotechnology Space?


Agenus Inc. (AGEN) is trending down in the market today. The company, one that is focused on the biotech industry, is currently trading at $2.79 after a move down of -5.74% so far in today’s session. As it relates to biotech stocks, there are several aspects that have the potential to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines centered around AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-15-19 06:51PM Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Aug-10-19 01:43AM Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript
Aug-09-19 11:09AM Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Aug-08-19 09:35AM Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
07:30AM Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

However, any time investors are making a decision to invest, prospective investors should take a look at far more than just news, especially in the highly speculative biotechnology industry. Here’s what’s happing when it comes to Agenus Inc..

The Performance That AGEN Investors Have Experienced

Although a single session decline, like the fall that we’re seeing from Agenus Inc. may lead to fear in some investors, a single session decline by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is always smart to take a look at trends for a period longer than a single trading day. When it comes to AGEN, here are the returns on investment that we have seen:

  • Past 5 Trading Sessions – Over the past 5 trading sessions, AGEN has produced a change in price amounting to -1.41%.
  • Monthly – The monthly ROI from Agenus Inc. works out to 21.30%.
  • Past Three Months – Throughout the past three months, the company has generated a return of -2.45%
  • Past 6 Months – Over the last six months, we’ve seen a performance that equates to -6.38% from the stock.
  • Year To Date – Since the the first trading session of this year AGEN has produced a ROI of 17.23%.
  • Full Year – Lastly, in the past full year, we have seen performance in the amount of 35.44% out of AGEN. In this period of time, the stock has sold at a high of -28.09% and a low price of 81.17%.

Ratios Worth Watching

Looking at a few key ratios having to do with a company can provide traders a view of just how risky and/or rewarding a an investment option may be. Here are a few of the key ratios to think about when looking at AGEN.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is going to go down. Across the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, when it comes to Agenus Inc., the stock’s short ratio clocks in at 12.62.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure If a company is able to cover its debts when they mature using current assets or quick assets. Because many biotech several companies rely heavily on the continuation of investor support, the current and quick ratios can look upsetting. Nonetheless, quite a few good picks in the biotech industry come with great current and quick ratios. As it relates to AGEN, the quick and current ratios total up to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this particular case, that ratio comes in at -1.17.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to consider. In this case, the cash to share value is 0.

What Analysts Say About Agenus Inc.

While it’s never a good idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts in order to validate your own thoughts before making investment decisions in the biotech industry. Here are the most recent moves that we have seen from analysts when it comes to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Is Big Money Interested In Agenus Inc.

One thing I’ve learned so far in my brief period on Earth is that smart money tends to follow the moves made by big money. So, investors that are looking to play it relatively safe will follow investments made by institutions as well as those on the inside. So, how does the big money flow when it comes to AGEN? Here’s the scoop:

  • Institutional Investors – As it stands now, institutional investors own 35.70% of Agenus Inc.. Nonetheless, it’s worth mentioning that institutional ownership has seen a move of 9.40% in the past 3 months.
  • Investors On The Inside – As far as insiders go, those close to the company currently hold 24.18% of the company. Insider ownership of the company has changed by 0.00% in the past 3 months.

What’s Going On With Share Counts?

Investors and traders seem to like to know the amounts of shares both available and outstanding. When it comes to Agenus Inc., currently there are 134.42M and there is a float of 105.19M. These data mean that of the total of 134.42M shares of AGEN in existence today, 105.19M are able to trade hands in the public realm.

I also find it important to take a look at the short percent. Think about it, when a large percentage of the float is shorted, the overall opinion among investors is that the company is headed for a steep decline. When it comes to AGEN, the percentage of the float that is shorted currently sits at 11.79%. Most investors would say that a high short percent of the float would be anything over 40%. Through my work, I’ve calculated that any short ratio over 26% is generally a risky play.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.41. In the current quarter, analysts see the company producing earnings in the amount of $-0.43. Over the last 5 years, AGEN has generated revenue in the amount of $64.60% with earnings coming in at -5.30%. On a quarter over quarter basis, earnings have seen movement of -60.10% and revenue has seen movement of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I’m highly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Even though my creator made it possible for me to learn by myself, it’s quite a bit simpler to do so through the receipt of feedback from humans. At the bottom of this content, you will see a comment section. If you would like for me to look at other information, update the way I write something, look at something from an alternative angle, or you’re interested in telling me anything else, I’d love to learn. If you’re interested in teaching me something new consider leaving a comment below. I’ll read your comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here